Edition:
United Kingdom

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

2.15USD
5:22pm GMT
Change (% chg)

$0.05 (+2.38%)
Prev Close
$2.10
Open
$2.15
Day's High
$2.15
Day's Low
$2.10
Volume
12,011
Avg. Vol
218,656
52-wk High
$5.75
52-wk Low
$1.58

Select another date:

Thu, Nov 9 2017

BRIEF-Acelrx Pharmaceuticals posts Q3 loss of $0.28 per share

* Acelrx pharmaceuticals reports third quarter 2017 financial results

AcelRx Pharma shares sink as FDA rejects opioid painkiller

Shares of AcelRx Pharmaceuticals Inc plunged more than 60 percent on Thursday after the U.S. Food and Drug Administration declined to approve its opioid painkiller Dsuvia.

UPDATE 4-AcelRx Pharma shares sink as FDA rejects opioid painkiller

* Shares tumble as much as 62.6 pct to $2.00 (Adds CEO comments)

BRIEF-AcelRx Pharma receives Complete Response Letter from the FDA for Dsuvia™ NDA

* AcelRx Pharmaceuticals receives Complete Response Letter from the FDA for Dsuvia™ NDA

FDA rejects AcelRx Pharma's pain drug

Oct 12 U.S. health regulators did not approve AcelRx Pharmaceuticals Inc's drug Dsuvia in its present form for the management of acute pain in trauma and ambulatory settings, the company said on Thursday.

BRIEF-Acelrx pharmaceuticals says co entered into 2nd amendment with Patheon Pharma

* Acelrx Pharmaceuticals - on August 22, co entered second amendment to manufacturing services deal effective as of august 4, 2017, with Patheon Pharma

BRIEF-Acelrx Pharmaceuticals Q2 loss per share $0.29

* Acelrx Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

BRIEF-AcelRx Pharmaceuticals reports successful outcome of Zalviso phase 3 IAP312 study on device functionality

* Acelrx Pharmaceuticals reports successful outcome of zalviso phase 3 IAP312 study on device functionality

BRIEF-Acelrx Pharmaceuticals appoints Raffi Asadorian CFO

* Acelrx Pharmaceuticals appoints Raffi Asadorian as chief financial officer

Select another date: